Literature DB >> 8844879

Gonadotrophin hormone releasing hormone agonist in cases of severe paraphilia: a lifetime treatment?

F Thibaut1, B Cordier, J M Kuhn.   

Abstract

Six patients with severe paraphilia were treated with a long-acting gonadotrophin hormone releasing hormone analogue (GnRH-a). In five cases, the antiandrogen treatment ended their deviant sexual behaviour and markedly decreased their sexual fantasies and activities without significant side-effects. The beneficial effects of this treatment were maintained for 7 years in the patient where there was the longest follow-up. Two patients abruptly withdrew front their antiandrogen treatment at the end of the first and third year, respectively. Both relapsed within 8-10 weeks. One of them asked for resumption of antiandrogen treatment. In another case, in order to phase out antiandrogen treatment, testosterone (T) was added to the GnRH-a. In spite of normal T levels, and of resumption of normal sexual activities and deviant fantasies, deviant sexual behaviour did not return. A smoother phasing out of GnRH-a treatment is thought to be better than an abrupt withdrawal. However, the duration of antiandrogen treatment necessary to ensure a complete disappearance of deviant sexual behaviour remains uncertain, but is at least 4 years.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8844879     DOI: 10.1016/0306-4530(96)00004-2

Source DB:  PubMed          Journal:  Psychoneuroendocrinology        ISSN: 0306-4530            Impact factor:   4.905


  9 in total

Review 1.  A Systematic Review of Behavioral Health Interventions for Sex Offenders With Intellectual Disabilities.

Authors:  Phillip L Marotta
Journal:  Sex Abuse       Date:  2016-08-02

Review 2.  Interventions for learning disabled sex offenders.

Authors:  L Ashman; L Duggan
Journal:  Cochrane Database Syst Rev       Date:  2008-01-23

3.  [Failure of a study in forensic psychiatric hospitals : Clinical trial to investigate the additive effect of triptorelin on the efficacy of psychotherapy].

Authors:  Peer Briken; Jürgen L Müller; Wolfgang Berner; Rolf-Hasso Bödeker; Jochen Vollmann; Christian Kasperk; Matthias Koller
Journal:  Nervenarzt       Date:  2017-05       Impact factor: 1.214

Review 4.  Current concepts in the pharmacotherapy of paraphilias.

Authors:  Frederico D Garcia; Florence Thibaut
Journal:  Drugs       Date:  2011-04-16       Impact factor: 9.546

Review 5.  Pharmacologic treatment of sex offenders with paraphilic disorder.

Authors:  Frederico Duarte Garcia; Heloise Garcia Delavenne; Alessandra de Fátima Almeida Assumpção; Florence Thibaut
Journal:  Curr Psychiatry Rep       Date:  2013-05       Impact factor: 5.285

Review 6.  Epidemiology and treatment of juvenile sexual offending.

Authors:  Priscille Gerardin; Florence Thibaut
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

7.  Therapeutic Effects of Leuprorelin (Leuprolide Acetate) in Sexual Offenders with Paraphilia.

Authors:  Jong Hyuk Choi; Jae Woo Lee; Jang Kyu Lee; Soyeong Jang; Mi Yoo; Dae-Bo Lee; Jeong-Won Hong; Il Suk Noh; Myung Ho Lim
Journal:  J Korean Med Sci       Date:  2018-07-23       Impact factor: 2.153

8.  A Case of Paraphilia with Osteoporosis and Administered with Depot Leuprorelin.

Authors:  Dohee Kim; Kyoung Min Kim; Myung Ho Lim
Journal:  Medicina (Kaunas)       Date:  2019-10-20       Impact factor: 2.430

9.  A case of mental retardation with paraphilia treated with depot leuprorelin.

Authors:  Woo Sung Park; Kyung Min Kim; Yong Woo Jung; Myung Ho Lim
Journal:  J Korean Med Sci       Date:  2014-09-02       Impact factor: 2.153

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.